Biotech · Private company
UroGen Pharma Ltd.
Track this companyFree. Adds UroGen Pharma Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials103 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- TURBTPhase 3 · Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- UGN-101 instillationsPhase 3 · CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- UGN-101 instillationsPhase 3 · Carcinoma, Transitional CellClinicalTrials.gov · fetched Nov 12, 2026
- UGN-102Phase 3 · Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- UGN-103Phase 3 · Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- UGN-104Phase 3 · Upper Urinary Tract Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- GemcitabinePhase 1 · Non-muscle Invasive Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- UGN-201Phase 1 · Non-muscle Invasive Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- UGN-301Phase 1 · Non-muscle Invasive Bladder CancerClinicalTrials.gov · fetched Nov 12, 2026
- Jelmyto (mitomycin) for pyelocalyceal solutionUrothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial CancerPHASE3 · RECRUITING · started Aug 6, 2025ClinicalTrials.gov NCT06774131 · fetched Nov 12, 2026
- A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder CancerPHASE3 · COMPLETED · started Aug 29, 2024ClinicalTrials.gov NCT06331299 · fetched Nov 12, 2026
- uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With JelmytoRECRUITING · started Nov 17, 2023ClinicalTrials.gov NCT05874921 · fetched Nov 12, 2026
- A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)PHASE1 · COMPLETED · started Jun 1, 2022ClinicalTrials.gov NCT05375903 · fetched Nov 12, 2026
- A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 1, 2022ClinicalTrials.gov NCT05243550 · fetched Nov 12, 2026
- Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)PHASE3 · COMPLETED · started Nov 30, 2021ClinicalTrials.gov NCT05136898 · fetched Nov 12, 2026
- A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerPHASE3 · TERMINATED · started Feb 19, 2021ClinicalTrials.gov NCT04688931 · fetched Nov 12, 2026
- Efficacy and Safety of UGN-101 in Recurrent PatientsPHASE3 · WITHDRAWN · started Oct 1, 2019ClinicalTrials.gov NCT04006691 · fetched Nov 12, 2026
- A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder CancerPHASE2 · COMPLETED · started Oct 15, 2018ClinicalTrials.gov NCT03558503 · fetched Nov 12, 2026
- The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC StudyPHASE3 · COMPLETED · started Apr 4, 2017ClinicalTrials.gov NCT02793128 · fetched Nov 12, 2026